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Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset 
muscular dystrophy which has a wide variety of symptoms, but is known for its classic 
symptom myotonia. Myotonia is the ability to contract, but not relax one’s muscles. The 
mis-splicing of a chloride channel gene Clcn1 causes myotonia in DM1 patients. To 
address symptoms such as myotonia, this thesis aims to test the effect of two potential 
treatments, heptamidine and furamidine, on splicing events in a DM1 mouse model.  
The HSALR mouse model replicates the tri-nucleotide CTG repeat that DM1 
patients have in the 3’ UTR of the DMPK gene. Repeats in affected individuals range 
from 38 to more than thousands. This transgenic mouse expresses 220 CUG repeats 
which form a toxic RNA structure. Like a sponge, the toxic RNA soaks up the MBNL 
proteins. MBNL proteins are responsible for regulating the alternative splicing of fetal 
vs. adult isoforms of more than 200 splicing events. When sequestered, the MBNL 
proteins can no longer regulate these events, resulting in mis-splicing of its targets (such 
as Clcn1), leading to the symptoms of the disease (like myotonia). 
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Two small molecules have been shown to rescue (reverse) mis-splicing in the 
transgenic mouse model. Heptamidine and furamidine were each administered to three 
sibling-matched mice. Three additional mice, which also expressed the CUG repeats, 
did not receive drug treatment as a control. Their transcriptomes were sequenced and a 
MISO (Mixture-of-Isoforms) splicing analysis was preformed to quantify and visualize 
splicing rescue across treatments. Gene expression changes were visualized to compare 
treatment off-target effects. This quantitation and comparison will confirm and identify 
known splicing biomarkers of DM1, leading to an improved understanding of how these 
small molecules are acting at a molecular level. This knowledge will inform future drug 
design to treat DM1 and other diseases caused by toxic repeat RNA.  
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INTRODUCTION 
Myotonic dystrophy type 1 (DM1), the most common form of adult-onset 
muscular dystrophy, does not yet have a cure. Individuals with DM1 have difficulty 
with daily tasks such as picking up a mug or grabbing a door knob, because they cannot 
seamlessly relax their muscles and release from these objects. This is the classic 
symptom of DM1: myotonia. Yet for many patients with myotonic dystrophy, myotonia 
is not their biggest complaint, instead it’s gastrointestinal dysfunction, regurgitation, 
and dyspepsia which interfere with daily life [3]. Interestingly, while it’s not reported as 
frequently in the literature, the 20-something DM1 patients I saw while shadowing in a 
muscular dystrophy clinic reported fatigue and sleepiness as being the most frustrating 
symptom. Thus, many take prescribed stimulants or self-medicated via copious amounts 
of caffeine, which can have their own effects on one’s body. DM1 itself is a 
multisystem disorder “affecting skeletal muscle as well as eyes, heart, gastrointestinal 
tract, endocrine system, and central nervous system” [2].  
While there are two forms of myotonic dystrophy with similar molecular 
mechanisms, DM1and DM2, DM1 most commonly affects adolescents and young 
adults. With a prevalence of 1 in 8000 individuals, DM1 is twice as common as two 
well-known diseases: Hodgkin Lymphoma and Huntington’s disease [2]. There are 
three clinical diagnoses denoting the severity of an individual’s symptoms: mild, 
classic, and congenital. While symptoms manifest on a spectrum, classic DM1 
symptoms include cataracts, myotonia, and cardiac conduction abnormalities and 
reduced life span, whereas patients with congenital myotonic dystrophy have early 
childhood onset of severe symptoms [4, 15]. Adult-onset myotonic dystrophy symptoms 
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vary greatly between patients, and depend largely on the extent of the disease-causing 
genetic mutation. Complications due to muscle wasting in both heart and lungs lead to 
early patient mortality, most commonly due to respiratory muscle failure and cardiac 
abnormalities [17]. Symptoms also increase in severity with successive generations, and 
as an adult onset disease, most individuals are not aware they have the disease before 
they have children. Due to its autosomal dominant nature, children of a parent with 
DM1 have a 50 percent chance of inheriting the disease-causing mutation, which can 
cause feelings of guilt. Additionally, one-third of DM1 patients are diagnosed with 
depression in the early stages of disease onset, accompanied by increased levels of 
apathy, reduced initiative, and fatigue [22].  
With the goal of improving treatment available to patients with DM1, this 
project uses bioinformatics, or computational biology, to explore two potential 
treatments: small-molecules heptamidine and furamidine. While this thesis focuses on 
the splicing analysis of a DM1 mouse model treated with small molecules, addressing it 
without integrating the social impact seems shallow.  
In combination with finding a treatment for patients with DM1, another issue 
arises: the difficulty of writing about biomedical research with empathy and 
understanding of patient’s experiences. Many emotions can come with diagnoses of 
neuromuscular diseases that can generate fear, apprehension, and guilt which are not 
caused by the disease-causing mutation. Muscle strength also begins to weaken, leading 
to decreased ability to perform daily tasks. I intend to capture the weight of this disease 
as I discuss process of my thesis. In writing about diseases like myotonic dystrophy, we 
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must wrestle with the reality that these genetic diseases affect much more than pure 
gene expression, affecting quality of life above all else.    
 I gained a more holistic understanding of myotonic dystrophy by getting outside 
of the lab through shadowing Dr. Subramony in his muscular dystrophy clinic in July 
2016. I had the opportunity to understand patient afflictions through their visit with a 
specialist, which may have been an initial or follow-up visit. While there are the 
occasional drug trials that patients can participate in, for most DM patients the current 
care plan included symptom tracking and management. Overall, these patients were 
actively invested in the DM scientific and patient communities, and surprised me with 
their resiliency and general positivity. Most patients had come to terms with their 
disorder, had undergone genetic testing, and were looking forward to maintaining as 
much muscular strength as possible.  
Speaking with patients at the community research symposium also affirmed the 
importance of this project. While these potential therapeutics may not be released 
individually, an understanding of their mechanisms of action will provide knowledge 
for informed future drug design for use with patients.  
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BACKGROUND  
Myotonic Dystrophy Physiology and Molecular Mechanism 
At the molecular level, DM1 is caused by a three-nucleotide CUG repeat in the 
RNA of the 3’ untranslated region of the dystrophia myotonica protein kinase (DMPK) 
gene on chromosome 19, shown in Figure 1 [27]. 
 
Figure 1. The location of DM1 expansion mutation in A) DNA and B) RNA gain-of-function 
structures. These structures lead to the sequestration of MBNL proteins. Figure was adapted 
from Figure 1 of [13]. 
 
While an unaffected individual may have anywhere from 5-37 CUG repeats, an 
individual with DM1 may have 38-4000 CUG repeats, with the number of repeats 
correlating with disease severity [10, 24]. This toxic RNA structure soaks up 
muscleblind-like proteins (MBNL) like a sponge absorbs water, due to binding sites on 
MBNL proteins for the CUG-repeats [20]. MBNL proteins are a family of proteins that 
regulate alternative splicing and determine which version of the gene (fetal or adult) is 
expressed in a cell at a given time [15]. Toxic RNA also forms nuclear foci, which 
concentrate in the nucleus and provide a high density of MBNL binding sites and a 
cellular environment where MBNL activity is lost [18]. When MBNL is sequestered to 
this toxic RNA structure and retained in the nucleus, it cannot regulate alternative 
A. 
-- DMPK 
normal (5--t37) 
---t------- (A)n 
B. 
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splicing elsewhere (Figure 2). Thus, many gene targets of MBNL are mis-spliced, 
leading to the variety of symptoms.  
 
Figure 2. Pathogenic mechanism of nuclear foci in DM1 fibroblast cells. Figure adapted from 
[7]. Visualization of co-localization of MBNL and nuclear foci in the nucleus of DM1 cells by 
overexpression of green fluorescent protein (GFP)-tagged MBNL, and immunofluorescence. I) 
control fibroblast cells which were transfected with MBNL-GFP. J) DM1 fibroblast cell 
transfected with MBNL-GFP. K) DM1 fibroblast cell with CUG-repeat RNA labeled in red. L) 
Co-localization of MBNL and CUG-repeat containing nuclear foci are shown, indicating that 
MBNL aggregates on the CUG repeats in the DMPK repeat containing transcript, limiting the 
supply of free MBNL for alternative splicing regulation.  
Understanding Splicing  
Cells have developed mechanisms for processing genetic material to turn on and 
off protein expression in response to environmental cues. Splicing, which removes non-
protein coding parts of DNA, is one such mechanism. Some of these non-protein coding 
portions of the DNA are called introns, while the transcribed portions of the DNA are 
called exons. To generate the proper set of proteins in the cell (given specific 
environmental conditions and other cell signaling) these pre-mRNA transcripts must be 
processed, or spliced (Figure 3A). However, as each cell contains the organism’s entire 
DNA, some exons will be necessary in some cells and not in others: this process is 
referred to an alternative splicing (Figure 3B).  
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Figure 3. Splicing is carried out on the newly transcribed RNA. Not all parts of the 
RNA are protein coding, thus the exons are spliced together and the introns are 
removed. The exons code for protein, and when pre-mRNA is fully processed into 
mature RNA (mRNA), it can be translated into proteins. All exons can be included (A), 
or exons can be skipped (B). Skipped exons, or cassette exons, are specific sequences 
that are required in some proteins, but not others (depending on the cell type, 
developmental stage, etc.). In this example, exon 2 can be either included or excluded 
in the processed mRNA, depending on what signals the cell is receiving.  
If proteins that regulate alternative splicing are sequestered and cannot regulate 
this process, then improper gene forms are expressed and disease symptoms displayed. 
In patients with DM1, the set of mis-spliced genes includes Clcn1, the mis-splicing of 
which directly results in the symptom myotonia. Muscle weakness has also been 
correlated with numerous splicing defects. Thus, addressing mis-splicing could directly 
affect symptoms of myotonic dystrophy [15]. 
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A Clinical Perspective 
While a cure for DM1 is currently non-existent, there are some therapies that 
patients with DM1 can access to help alleviate symptoms. To determine a patient care 
plan, physicians refer patients to neurologists when they suspect there is a neurological 
component to their disease. Once referred, patients may see a neuromuscular specialist 
such as Dr. S. Subramony, whom I shadowed at the University of Florida. Then 
physicians typically do a neurological assessment to diagnose, which may lead to 
genetic testing, the ability to sign up for drug trials, or physical tools such as orthotics to 
accommodate their worsening symptoms. They may receive various occupational 
therapies, such as hand training to counteract the myotonia, physical therapy, orthotics, 
and mobility therapy [1]. Neuromuscular specialists may also determine if patient could 
benefit from such therapies due to their range of motion and presence of residual muscle 
strength, a proxy for the presence of substantial muscle fibers [1]. While functional 
training, like hand therapy, will not cure symptoms, it contributes to an individual’s 
abilities to live as independently and functionally as possible [1].  
Other treatment is more medicalized. A review by Thornton et al. gives an 
overview of the current approaches to DM1 therapy. There are four mechanistic 
approaches including transcriptional silencing, post-transcriptional silencing, inhibiting 
interactions between MBNL and toxic RNA, and targeting pathways downstream of 
RNA toxicity [18]. While these approaches have yet to be fully-cleared for patient use, 
erythromycin, an antibiotic, reduces toxic RNA most successfully in comparison to 20 
FDA-approved small molecules [14]. With no toxicity to humans, oral erythromycin 
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could prove the most effective therapy by reversing splicing and improving myotonia 
[14]. 
Current research also includes genome editing via CRISPR-Cas9 and stem cell 
therapy that could restore tissue health. A preliminary study conducted in 2015 shows 
that inserting a poly-A signal (a signal for early transcriptional termination) before the 
pathogenic repeat in the DMPK gene inhibits production of toxic RNA [23]. While this 
method could provide targeted tissue repair, such as in muscles, it’s unlikely to be 
widely feasible until there are methods to grow and edit patient-derived stem pluripotent 
stem cells in a timely and cost-effective manner. However, once stem-cell therapies 
become more and more integrated into treatment of diseases, this may serve as an 
effective treatment free of off-target effects. CRISPR-Cas9 has also been used recently 
as a therapeutic via genome editing of removing the DMPK CUG repeat itself [19]. 
Again, CRISPR/Cas9 genome editing may provide patients with another option; 
however, it may not fully repair cells in a patient, as it would be limited to specific sites. 
While in the early stages, genome editing may be the future of DM1 therapeutics as we 
move more towards personalized medicine.    
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Using Small Molecules to Disrupt MBNL1 Interactions with CUG Repeats 
Small molecules have been studied as potential therapeutics for treating DM1. 
Initially Warf et al. analyzed an FDA-approved anti-parasitic pentamidine, known to 
bind the minor groove of DNA, and they found that it could reverse splicing in a DM1 
cell culture model [21]. Analogs were developed by varying the linker length in the 
middle of the molecule, and those were tested for toxicity and splicing rescue in a DM1 
model [21]. This yielded heptamidine, which was found to rescue splicing through RT-
PCR analysis [6]. Furamidine, another small-molecule, has also been tested on 
genetically modified mice. Heptamidine, one of the small molecules analyzed in this 
study, was previously shown rescue of splicing of two genes: Clcn1 and Atp2a1 (Figure 
4). The HSALR transgenic mouse line was developed in 2000 to mimic DM1 symptoms 
with a CUG repeat length of 220 [12]. These HSALR mice have myotonia, and maintain 
approximately 81% of the alternative splicing consistent with DM1 patients, allowing 
for study of the splicing rescue of potential treatments [6, 15].    
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Figure 4. Dose-dependent rescue of mis-splicing of Clcn1 and Atp2a1 in HSALR mice treated 
with heptamidine. Data was recorded across a range of dosage of 0-30 mg kg‑1 of heptamidine 
administered for a seven-day course. WD represents withdrawal state of 10-days post-treatment. 
An increase in dosage to 20 mg kg-1 heptamidine decreased the percentage of exon inclusion of 
Clcn1 exon 7a to WT levels. In exon 22 of Atp2a1, percent exon inclusion directly correlated 
with increased heptamidine dosage reaching a peak of 60% inclusion with a dosage of 30 mg 
kg‑1 [6]. 
 
This mis-splicing rescue demonstrates promising results of a potential treatment 
for patients with DM1. Heptamidine was administered to transgenic mice with a 
CUG220 repeat. Previous literature shows Atp2a1 mis-splicing was not completely 
rescued by heptamidine, but was significantly improved. In the Clcn1 gene, MBNL 
regulates the exclusion of exon 7a. When MBNL is sequestered by the CUG repeats, the 
mis-splicing in Clcn1 leads to chloride channelopathy (dysfunction of the chlorine ion 
channel), and causes the classic symptom myotonia. Furamidine has also been shown to 
rescue mis-splicing of Clcn1 exon 7a and Atp2a1 exon 22 using qRT-PCR (Figure 5) 
[16]. 
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Figure 5. Dose-dependent rescue of mis-splicing of Clcn1 and Atp2a1 in HSALR mice 
treated with furamidine. Data was recorded across a range of dosage of 0, 10, and 20 mg 
kg‑1 of furamidine administered over a seven-day course. WD represents withdrawal state 
of 10-days post-treatment. An increase in dosage to 20 mg kg-1 furamidine decreased the 
percentage of exon inclusion of Clcn1 exon 7a approximately WT levels. In exon 22 of 
Atp2a1, percent exon inclusion directly correlated with increased furamidine dosage 
reaching a peak of upwards of 80% inclusion with a dosage of 20 mg kg‑1 [16]. 
 
Heptamidine treatment also improves the symptom of myotonia in mice (Figure 
6). In both genes, mis-splicing returned during withdrawal state, indicating the drug is 
not permanently correcting the disease.  
 
Figure 6. Myotonia reduction upon treatment with heptamidine. Treatment yields a 
significant reduction in myotonia [6].  
  
§ 
·.; 
::, 
0 
100 
80 
~ 60 
ll 
w 
l 40 
c 
~ 
OJ 
a.. 
20 
-.--
Clcn 1 Exon 7 a 
•• 
• 
** 
• 
----..----
120 
100 
C: 
0 
·.; 
~ 80 
C: 
0 
X 60 w 
~ 
c 
OJ 40 
** 
e 
OJ 
a.. 
__!_.__ 20 
• 
o~--~---~---~---~ 0 
dosage (mg kg·') 0 
wt 
0 10 20 dosage (mg kg·') 
HSA'" 
Furamidine dosage 
Myotonia Reduction 
3 000 
.,, 
"cl 
~ 
2 
"' ·a 
0 
0 00 00 >, 
::E 
0 • 0 000 · 
0 20 30 
Heptamidine dosage (mg kg·1) 
Atp2a 1 Exon 22 
** 
• 
** •• 
--·-·--
. 
---------
0 0 10 20 
wt HSA'" 
Furamidine dosage 
 
 
  12 
While heptamidine may not cure DM1, it provides hope and knowledge for 
alleviating symptoms and halting the progression of muscle degeneration. A paper by 
Siboni et al. indicates furamidine acts on Clcn1 and Atp2a1 similarly, but with less 
toxicity. Our study is a continuation of the Coonrod et al. 2013 paper, with a narrowed 
focus on heptamidine and furamidine at a dosage of 30 mg kg-1 in hopes of further 
understanding the degree to which they affect splicing.  
Heptamidine relieves myotonia, and furamidine, an FDA-approved anti-
parasitic, also rescues the mis-splicing of Clcn1 exon 7a (the mis-spliced event causing 
myotonia); however, what other mis-splicing events are they beneficially or adversely 
affecting? And what can we learn about their overall effects on gene expression? The 
splicing analysis conducted in this study will have two main focuses: to confirm that 
previously-studied mis-splicing of genes Clcn1 and Atp2a1 has been relieved, and to 
evaluate the efficacy of these treatments by comparing them to DM1 splicing 
biomarkers.  
We will address these questions with a MISO analysis of RNA from transgenic 
mice. Through a gene expressions analysis and a splicing analysis, this study will yield 
further understanding of the way potential treatments function to alleviate patients of 
their debilitating symptoms. This thesis aims to combine current therapeutic research 
with a patient-focused understanding of the disease.  
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METHODS 
Sibling matched HSALR mice were treated by Masayuki Nakamori at Osaka 
University. Sibling matching ensures that genetic differences among individuals are 
highly controlled, as siblings will have the most similar genomes apart from identical 
twins [6]. Nine mice were treated, three mice per treatment, with saline (control), 30-mg 
kg-1 furamidine, and 30-mg kg-1 heptamidine. After seven days of treatment, the tibialis 
anterior muscle was removed. RNA was extracted and shipped to the Berglund Lab 
where it was stored at -80 °C before it was processed.   
To evaluate the state of RNA, the samples were sent to be analyzed using a 
fragment analyzer and showed partial degradation. This partial degradation could alter 
our analysis by affecting splicing coverage and gene expression, as certain genes or 
splicing junctions may have been stochastically degraded and thus not as well 
represented in the data. Regardless, we proceeded and adjusted post-sequencing to 
maintain adequate quality. 
 Protein-coding RNA, or messenger RNA (mRNA) is most important for our 
study, as the amounts of mRNA in a treated cell should vary among genes and show the 
molecular effects of furamidine and heptamidine. Since we cannot directly sequence 
RNA, we prepared DNA libraries from the RNA with the KAPA Stranded RNA-seq kit 
with Riboerase [30].  
Library Preparation  
Sequencing libraries (a collection of cDNA fragments to be sequenced), were 
prepared using the KAPA Stranded RNA-seq kit with Riboerase. The reasons for 
choosing this kit are two-fold: firstly, because our RNA was partially degraded, as 
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shown by the fragment analysis, a poly-A tail selection would be problematic, and 
secondly, per the recommendation of the sequencing facility and cost. The overview of 
the library preparation is shown in Figure 7. 
 
Figure 7. Schematic of Library Preparation. Adapted from the Bioo Scientific NEXT flex 
qRNA-seq RNA sample preparation which is also followed by the KAPA Stranded RNA-seq kit 
[25]. The workflow for the KAPA-stranded kit is similar [30]. 
 
 Qubit Fluorometric Quantitation was used to measure the concentration of RNA 
to standardize the amount of RNA used across samples (Appendix 2). The KAPA-
stranded kit procedure was followed apart from adding Bioo scientific molecular index 
adaptors in step 14 [20, 16].  
Overview of Pipeline 
Libraries were combined and sequenced on one lane using the NextSeq 500 
sequencer in the University of Oregon’s Genomics and Cell Characterization core 
facility. Using ACISS, the University of Oregon super computer, and HiperGator, the 
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University of Florida super computer, sequencing output was processed and analyzed 
using the workflow shown in Figure 8.  
 
Figure 8. Workflow of the RNA-sequencing splicing analysis. Steps in green were 
conducted by M. Nakamori at Osaka University in 2015. Read cleaning, genome 
alignments, and HTSeq were run by Dr. Leslie Coonrod. The bam file was indexed 
myself, and I ran DESeq2, MISO, compare MISO, visualized alternative splicing with 
IGV, and represented alternative splicing with GraphPad Prism.  
While three mice were treated with each drug (saline, furamidine, and 
heptamidine), only two heptamidine samples were analyzed as one sample, H-3, was 
removed from analysis due to its dis-similarity identified by an initial quality screening.  
MISO stands for Mixture of Isoforms and it “quantitates the alternative splicing 
of genes from RNA-seq data” [27]. MISO uses known splice site information from a 
skipped exons annotations file (provided in their online documentation), to identify 
splice sites in RNA-seq data and splicing rescue across treatments. MISO 
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documentation was followed with minimal deviance to answer questions about the 
splicing rescue ability of these small molecules.  
In pairwise comparisons between untreated and treated samples, MISO 
generates the estimate of the isoform (type of spliced gene) and the differential 
expression of isoforms for paired-end reads. MISO generates a Bayes factor for each 
event comparison, which is a quantitative statistical measure of differential expression 
of these isoforms [27]. These data were filtered with a minimal Bayes factor of 5, which 
is considered a substantial level of significance of the magnitude of splicing rescue, 
measured by present spliced in. These splicing events were compared to DM1 splicing 
biomarkers for less biased analysis, and to conclude more general effects on splicing.  
To visualize differential gene expression, and understand off-target effects, the 
python script HTSeq was used to generate counts of gene transcripts, and DESeq2, an R 
package, was used to compare treated to untreated samples [29, 26]. Genes identified by 
DESeq2 were differentially expressed in the top 1% of expression changes affected by 
treatment, designated by a p-value of 0.01.  
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RESULTS 
Heptamidine and Furamidine Rescue Splicing to Different Extents 
Splicing rescue with treatment of furamidine and heptamidine can be both 
quantified and visualized to explain their effect and significance on the DM1 HSALR 
model. Initially, two previously-identified splice sites were analyzed, Atp2a1 and Clcn1 
by Coonrod et al. Splicing, measured through PSI, percent exon inclusion, was 
quantified by MISO. Thirty-six splicing events were identified as mis-spliced in DM1, 
designated as ‘splicing biomarkers’ [15]. Splicing events that were significant with a 
Bayes factor of greater than five in both furamidine- and heptamidine-treated samples, 
that were also listed in the list of splicing biomarkers, are shown in Figure 9.  
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Figure 9. Percent Spliced In (PSI) across treatment in splicing biomarkers. Splicing 
biomarkers were identified in [15] and significant in both furamidine and heptamidine-
treated samples with error bars representing confidence intervals identified by MISO. 
The grey shading shows the difference between percent exon inclusion across wildtype 
and HSALR mice. Splicing was partially rescued in these events apart from Nrap exon 
12 where splicing was not rescued and was instead mis-spliced, and in Nfix exon 7 and 
Phka1 exon 28 where splicing was over-corrected.  
 
In the rescued splicing events shown in figure 8, 2/7 have better splicing rescue 
with furamidine treatment, while 5/7 events have better splicing rescue with 
heptamidine treatment.  
The mis-splicing event causing myotonia, Clcn1 exon 7a, shows a decrease in 
exon inclusion of exon 7a to wildtype-like levels. Wildtype mice have a mean exon 
inclusion of 10%, while control (disease) mice have inclusion of 30%. With 
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administration of furamidine exon inclusion levels decrease to 21% while they decrease 
to 13% with heptamidine treatment (Figure 10). 
 
Figure 10. Clcn1 exon 7a percent spliced in across treatments. Wildtype mice have 
about 10% inclusion of Clcn1 exon 7a, while the disease-state mice have inclusion of 
30%. Treated mice have partially-restored splicing of 21% inclusion with furamidine 
treatment and 13% exon inclusion with heptamidine treatment. Confidence intervals 
indicate that the mean percent exon inclusion changes are not significant (Bayes factor 
<5) between HSALR and furamidine, and HSALR and heptamidine. 
 
Splicing rescue of Atp2a1 exon 22 with the number of sequencing reads 
spanning the splicing junctions are shown (Figure 11); Atp2a1 exon 22 is partially 
rescued upon treatment of heptamidine and furamidine (Figure 9A, 11).  
Clcnl Exon 7a 
4 
t t I 
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Figure 11. Splicing of gene Atp2a1 exon 22 across treatments. In the wildtype, exon 22 
is included. In the control sample (disease-state) exon 22 is excluded, shown in red, in 
comparison to the inclusion of exon 22 with treatment by furamidine and heptamidine 
which aligns more with wildtype-like exon inclusion.  
The average number of reads spanning splicing junctions in Atp2a1 exon 22 
splicing is approximately 12,200 reads in comparison to an average of 17 reads across 
Clcn1 exon 7a. While exon 7 splicing is corrected in a positive direction, the number of 
reads spanning the exon junction are not sufficient to draw significance as shown by the 
large confidence intervals in Figure 9 and the sashimi plot showing reads in Figure 12. 
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Figure 12. Splicing junction of Clcn1 exon 7a across treatments. Mice treated with 
heptamidine have significantly better splicing rescue than those treated with furamidine 
although they are also rescued in a positive direction. Reads spanning the junction are 
minimal in all treatments.  
 
Heptamidine and Furamidine Rescue Splicing of other DM1 biomarkers 
Splicing events identified by MISO across treatments were gleaned for DM1 
splicing biomarkers [15]. Of 42 splicing biomarkers, 9 were significantly affected by 
both heptamidine and furamidine treatment. Two events were significantly affected 
only by heptamidine, one was exclusively affected by furamidine, and 30 were either 
not found in our data or not significant (Figure 13). Full splicing biomarker PSI mean 
and confidence intervals across treatments are listed in Appendix 2, Table 1.  
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Figure 13. Splicing Rescue of DM1 splicing biomarkers by treatment. Forty-two 
splicing events were identified as splicing biomarkers of DM1 [15]. Of these, 9 were 
positively rescued by both heptamidine and furamidine, 2 were affected only by 
heptamidine, one was affected only by furamidine, and 30 were either not found in the 
data, or did not show significant splicing rescue.    
Furamidine Heptamidine 
DMl Splicing 
Bio markers 
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Heptamidine and Furamidine Have Contrasting Effects on Gene Expression 
Treatment with furamidine significantly affects gene expression less than 
treatment with heptamidine, indicating different mechanisms of action and off target 
effects (Figure 14). Genes that were significantly over- or under-expressed with a p-
value of 0.01 or less in comparison to the control are shown in red, while the genes that 
are not significantly different are shown in grey. A p-value of 0.01 indicates that these 
genes are highly significant in their deviation from normal gene expression.  
 
Figure 14. Differential gene expression with treatment of heptamidine and furamidine. 
Genes with differential expression to a p-value of less than 0.01 are shown in red. A) 
Treated by heptamidine 4465 genes were over-expressed (16.7%), and 4228 genes were 
under-expressed (15.7%). B) Treated with furamidine, 108 genes were over-expressed 
(0.39%), and 272 genes were under-expressed (0.99%).  
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DISCUSSION 
Treatment of transgenic mice with small molecules heptamidine and furamidine 
rescue splicing of numerous mis-spliced events in DM1; however, the limited power of 
our study limits our ability to confirm effects observed in other studies. While both 
heptamidine and furamidine have been shown previously to rescue mis-splicing in a 
mouse model and HeLa cells, respectively, this RNA-seq analysis requires deeper 
sequencing. Figures 9-11 show the overall positive effects of heptamidine and 
furamidine on splicing. In comparison to DM1 splicing biomarkers causing disease 
symptoms, these small molecules do benefit transgenic mice, and thus could aid 
patients. However, their toxicity must be weighed with efficacy.  
The gene expressions analysis, represented through DESeq2 plots demonstrate 
the off-target effects of both furamidine and heptamidine. As heptamidine is known to 
be toxic, the gene expression is consistent—where many genes are significantly affected 
by treatment. However, the gene expression plot of furamidine-treated mice show 
promise, as less than 1% of genes are differentially affected. This indicates that 
furamidine may be having few off-target effects and wouldn’t interfere in other cellular 
processes.  
The analysis of splicing using MISO showed splicing rescue of only two out of 
nine events previously studied in heptamidine. While the remaining 7/9 events trended 
positively, our study lacked the power to claim conclusive rescue (Bayes factor <5).  
Splicing effects were also considered with comparison to splicing biomarkers identified 
by Nakamori et. al [15]. Of these 36 events, nine of these events were significantly 
affected by furamidine and heptamidine. This may be due to the limitations of the 
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mouse model, the inadequate coverage of sequencing reads, or low gene expression 
levels. To get more coverage of splicing events, specifically Clcn1 exon 7a, sequencing 
of the RNA libraries could be repeated to a greater depth, generating more reads and 
thus more reads spanning splicing junctions. The main barrier to addressing this 
limitation is the substantial monetary investment. Since other small molecules are being 
investigated, which show better efficacy and lower toxicity, there would be limited 
benefit to performing more sequencing of these data.  
Limitations 
 Mouse models may not reveal all effects of treatment that could transpire in 
humans, for whom we intend to use the drugs. The HSALR model doesn’t replicate 
heart, central nervous system, or muscle weakness in mice [9]. The HSALR model also 
does not include at least 12 of the human DM1 mis-spliced events [15]. These splicing 
markers would only be able to be studied in human tissue culture, and thus that could be 
the next step of this study. Furthermore, the mouse model also uses 220 repeats, which 
fits in the classic clinical diagnosis of DM1, which isn’t extremely severe. Nakamori et 
al. showed a relationship between MBNL alternative splicing regulation and disease 
severity in human tissue, which would not be replicated through this model. They also 
suggest that “other splicing factors are also sequestered or indirectly affected through 
the activation of regeneration or stress response pathways” [15].  
Future studies could address the number of replicate mice. As only three mice 
were treated with each drug there are few replicates, although this is rather maximal for 
sibling-matched mice. However, with a greater number of mice in the same generation 
of this transgenic mouse line, there may be ability to compare across numerous samples 
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to avoid the genomic differences that accompany different individuals. Regardless, to 
examine at splicing of three mice of each treatment, and two mice treated with 
heptamidine, these files were concatenated to run one ‘sample’ at once through MISO. 
This may have reduced the power of this study as well. Alternate software that can take 
replicates into account could be used to confirm these results and analyze the splicing 
across replicates: rMATS [28].  
Despite limitations, our findings aid the development of new treatments and 
experiments to address symptoms of DM1 While the field of DM1 research is 
constantly evolving, this analysis fits into the niche of understanding the molecular 
basis for drug treatment and pre-clinical analysis of treatments.  
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CONCLUSION 
Realistically, the likelihood of using heptamidine or furamidine for patients is 
slim; however, this analysis still adds to the body of knowledge of potential treatments. 
This analysis of splicing rescue could be used to develop new therapeutics by 
modifying their chemistry to be less toxic and to target specific cell types. If the 
scientific community better understands the exact mis-splicing in the disease, future 
drugs may be tailored to correcting specific mis-splicing events. Heptamidine and 
furamidine may also be combined with other drugs in a drug cocktail to be taken by 
patients, as they do generally positively affect DM1 mis-splicing events.  
This analysis can be understood as an example of the many trial and errors of 
modern science. In the race to cure diseases, sometimes research yields imperfect 
treatments which propel future research, and other times we use toxic drugs out of 
desperation, for example with chemotherapy for cancers. However, in the case of DM1, 
the process of identifying a highly effective, FDA-approved, and non-toxic drug 
continues.  
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APPENDICES 
Appendix 1. RNA-seq Library Preparation 
The KAPA Stranded RNA-Seq Kit with RiboErase (HMR) kit was used for 
library preparation. The technical data sheet can be found at: 
https://www.kapabiosystems.com/product-applications/products/next-generation-
sequencing-2/rna-library-preparation-2/kapa-stranded-rna-seq-riboerase/. Quantities 
were calculated for preparation of nine libraries, and the procedure was followed with 
minimal exceptions. In step 14.3, an annealing temperature of 65 °C was used rather 
than 60 °C in accordance with the enzyme specificity. In step 14, master mix was 
prepared using Next Flex Universal F primer, each sample was assigned a barcoded 
primer. Barcoded primer information can be accessed at: 
http://www.biooscientific.com/Portals/0/Manuals/NGS/5130-11-NEXTflex-qRNA-Seq-
Kit-v2.pdf. 
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A
ppendix 2. Table 1 
Table 1.  Percent Exon Inclusion A
cross Treatm
ents and Splicing Biom
arkers 
 
* indicates significant changes w
ith a Bayes factor >5 com
pared to H
SA
LR 
 
WT PSI mean Control PSI Furamidine PSI Heptamidine PSI 
Splice event (low CI-high mean (low CI- mean (low Cl-high mean (low CI-high Effect of splicing 
Cl) high Cl) CI) Cl) change 
ATP2A1 exon 22 100 (NA) 28 (28-29) 57 (57-58)* 54 (53-54)* Ca++ reuptake 
NFIX exon 7 40 (25-58) 44 (40-48) 31 (28-35)* 28 (23-33)* transcription factor, 
myogenesis 
INSR exon 11 13 (3-29) 17 (11-26) 24 (16-34) 23 (17-29) insulin signaling (t. 
signal ing) 
CAPZB exon 8 85 (77-91) 93 (90-95) 91 (89-94) 92 (89-94) assembly of actin 
filaments 
CACNA1S exon 29 40 (32-50) 87 (84-89) 94 (92-96)* 93 (90-96) excitation contraction 
coupling (1' Ca++ entry) 
CAMK28 exon 13 57 (36-78) 19 (16-23) 38 (33-42)* 41 (35-48)* Signaling 
VPS39 exon 3 61 (15-96) 7 (1-21) 16 (7-35) 14(3-35) vesicle trafficking, 
TGFbeta signaling 
CLCNl exon 7a 10 (4-18) 30 (22-38) 21 (15-27) 13 (4-26) chloride channel (loss of 
ion conductance) 
LDB3 exon 11 6 (3-10) 68 (63-73 39 (36-43)* 24 (19-30)* Z disc 
GFPTl exon 9 81 (42-100) 80 (67-90) 82 (71-91) 81 (68-92) protein glycosylation ( .!, 
feedback inhibition) 
MBNLl exon 7 2 (0-3) 33 (28-38 19 (16-23)* 16 (13-19)* alternative splicing ( 1' 
nuclear localization) 
NRAP exon 12 57 (54-59) 58 (56-60) 63 (61-65)* 75 (74-76)* myofibril assembly 
ANK2 exon 21 89 (74-98) 53 (29-90) 62 (40-85) 69 (40-98) membrane targeting 
OPAl exon 4b 30 (23-37) 28 (22-35) 38 (31-45) 43 (33-52) mitochondrial dynamics 
RYRl exon 70 57 (51-62) 81 (79-83) 82 (80-84) 81 (79-83) Ca++ release ( .!, open 
probability) 
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* indicates significant changes w
ith a Bayes factor >5 com
pared to H
SA
LR 
 
Splice event WT PSI mean Control PSI mean Furamidine PSI mean Heptamidine PSI mean Effect of splicing change (low Cl-high Cl) (low Cl -high Cl) (low Cl -high Cl) (low Cl-high Cl) 
COPZ2 exon 9b 7 (1-32) 4 (1-8) 7 (3-13) 3 (1-9) vesicle trafficking 
PHKAl exon 28 28 (25-31) 14 (13-16) 25 (23-28)* 42 (37-48)* muscle glycogenesis 
FHODl exon lla 33 (10-72) 34 (11-61) 33 (16-56) 47 {14-79) actin organization 
MBNL.2 exon 7 15 (12-19) 21 (17-25) 15 (12-19) 31 (26-37)* alternative splicing 
DMD exon 78 97 (91-100) 99 (97-100) 99 (96-100) 99 (98-100) membrane integrity 
MLFl exon 3 89 (85-92) 70 (64-76) 63 (57-68) 41 (32-52)* oncoprotein 
ABLIM2 exon 12 65 (35-88) 82 (62-97) 82 (61-98) 89 (68-99) z disc 
8/Nl exon 11 0(0-1) 5 {4-6) 2 (2-3)* 1(1-2)' T-tubule formation (-1, 
formation ofT tubules) 
LDB3 exon 5 72 (65-79) 92 (91-94) 85 (83-87)* 83 (79-88)* z disc 
TXNL4A exon 4 5 (1-13) 2 (1-5) 3 (1-6) 2 (1-5) PQBPl binding protein 
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Appendix 3. Table 2 
Table 2. Library Preparation Information 
   
NextFlex 
Sample 
Treatment 
µLRNA 
µLH20 Qubit Molecular 
name (408 ng) ng/µL Index 
Adapter 
C-1 Saline 7.1 2.9 57.5 Al 
C-2 Saline 7.17 2.83 56.9 A2 
C-3 Saline 5.51 4.49 74 A3 
H-1 30 mg/kg 7.65 2.35 53 .3 A4 
heptamidine 
H-2 30 mg/kg 10 0 40.8 AS heptamidine 
H-3 30 mg/kg 7.35 2.65 55.5 A6 
heptamidine 
F-1 30 mg/kg 7.11 2.89 57.4 A7 furamidine 
F-2 30 mg/kg 8.85 1. 15 46.1 A8 
furamidine 
F-3 
30 mg/kg 
7.27 2.73 56.1 A9 
furamidine 
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Appendix 3. MISO Pipeline run on the HiperGator command line 
module load ufrc 
srundev --time=4:00:00 
module load python/2.7.6 samtools 
python /home/eric.t.wang/Tools/pythonmodules/lib/python2.7/site-packages/misopy/ 
 
1. Example Sam to bam script in HiperGator:  
python /ufrc/berglund/npellit3/2016_mouseRNAseq/sam_to_bam.py \ 
--convert /ufrc/berglund/npellit3/2016_mouseRNAseq/datanew/saline.sam \ 
/ufrc/berglund/npellit3/2016_mouseRNAseq/datanew/BAM \ 
--ref 
/ufrc/berglund/npellit3/2016_mouseRNAseq/miso/Mus_musculus.GRCm38.68.dna.toplevel.fa.f
ai 
 
2. Example MISO script in HiperGator: 
python /home/eric.t.wang/Tools/pythonmodules/lib/python2.7/site-packages/misopy/miso.py \ 
--run /home/npellit3/2016_mouseRNAseq/miso/annotations/SE_indexed/ \ 
/home/npellit3/2016_mouseRNAseq/data2/Fur.sorted.bam \ 
--output-dir /home/npellit3/2016_mouseRNAseq/data2/Fur/ \ 
--read-len 66 \ 
--settings-filename /home/npellit3/2016_mouseRNAseq/miso/settings.txt \ 
--use-cluster --no-wait --chunk-jobs 1000 
 
3. Example Compare MISO script in HiperGator: 
python /home/eric.t.wang/Tools/pythonmodules/lib/python2.7/site-
packages/misopy/compare_miso.py \ 
--compare-samples /ufrc/berglund/npellit3/actD/data2/wt/ 
/ufrc/berglund/npellit3/2016_mouseRNAseq/data2/controls/ \ 
/ufrc/berglund/npellit3/2016_mouseRNAseq/data2/compare/ 
 
4. Example Sashimi Plot script in HiperGator: 
python /home/eric.t.wang/Tools/pythonmodules/lib/python2.7/site-
packages/misopy/sashimi_plot/sashimi_plot.py \ 
--plot-event "chr8:84721643:84721818:-@chr8:84716141:84716288:-
@chr8:84713766:84713857:-"  
/ufrc/berglund/npellit3/2016_mouseRNAseq/miso/annotations/SE_indexed \ 
/ufrc/berglund/npellit3/2016_mouseRNAseq/miso/sashimi_plot_settings.txt \ 
--output-dir /ufrc/berglund/npellit3/2016_mouseRNAseq/miso2/sashimi/   
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Appendix 4. DESeq2 Script in R Studio 
library("DESeq2") 
directory <- "/Users/nataliepellitier/Desktop/Thesis!!!/HTSeq/" 
sampleFiles <- grep("furamidine", list.files(directory),value = TRUE) 
sampleFilescont <- grep("saline", list.files(directory),value = TRUE) 
sampleFiles <- c(sampleFiles,sampleFilescont) 
sampleCondition <- sub("\\d.genecount","\\1",sampleFiles) 
sampleTable <- data.frame(sampleName = sampleFiles, fileName = sampleFiles, condition = 
sampleCondition) 
ddsHTSeq <- DESeqDataSetFromHTSeqCount(sampleTable = sampleTable, directory = 
directory, design = ~ condition) 
ddsHTSeq$condition <- factor(ddsHTSeq$condition, levels=c("saline","furamidine")) 
dds <- DESeq(ddsHTSeq) 
res <- results(dds) 
res <- res[order(res$padj),] 
head(res) 
summary(res) 
plotMA(res, alpha=0.01, ylim=c(-5,5))   
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